Lantheus jumps after Q1 2026 results and reaffirmed 2026 guidance
Lantheus reported first-quarter 2026 results and reaffirmed full-year 2026 guidance. The update also highlighted FDA approval of PYLARIFY TruVu with a phased launch planned for Q4 2026.
1. What happened today (May 7, 2026)
Lantheus released first-quarter 2026 financial results in a same-day 8-K and accompanying earnings press release, and the stock moved higher following the update. The company reaffirmed its previously issued full-year 2026 revenue and adjusted EPS outlook and provided business updates tied to its radiopharmaceutical portfolio.
2. Key numbers and guidance investors are reacting to
The press release disclosed Q1 2026 revenue of $377.3 million and GAAP diluted EPS of $1.80 (with adjusted diluted EPS of $1.46). Management reaffirmed full-year 2026 revenue guidance of $1.4 billion to $1.45 billion alongside reaffirmed full-year adjusted EPS guidance.
3. Product/regulatory items in the release
Alongside earnings, Lantheus highlighted FDA approval for PYLARIFY TruVu (a new formulation of PYLARIFY) and said a phased geographic commercial launch is planned to begin in the fourth quarter of 2026. The release also reiterated the FDA tentative approval for PNT2003 (Lutetium Lu 177 Dotatate), positioning it as a potential radioequivalent option in neuroendocrine tumors once final approval is available.